Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation

• Status: Completed
• Trial end date: 2008-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the efficacy of infliximab in reducing the incidence of grade II-IV acute graft versus host disease by day +100 post-transplant in patients undergoing allogeneic hematopoietic stem cell transplant.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ohio State University Comprehensive Cancer Center
• Treatments: Infliximab

Criteria

Inclusion Criteria:

• Patients undergoing allogeneic HCT for the following disorders:

• Acute myelogenous leukemia

• Acute lymphoblastic leukemia

• Non-Hodgkin's lymphoma

• Hodgkin's disease

• Multiple myeloma

• Chronic lymphocytic leukemia

• Chronic myeloid leukemia in accelerated or blast crisis at time of transplant.

• Age >20 yrs

Exclusion Criteria:

• Patients undergoing allogeneic stem cell transplantation for chronic myelogenous leukemia and aplastic anemia are excluded.

• Pregnant or breast-feeding females.